CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

-LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS

-CANbridge to Hold Investor Call

CANbridge to Participate in the Jefferies 2023 Global Healthcare Conference

CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection

-Data Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research

CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

-Novel Second-Generation SMA Gene Therapy Rescues Motor Function in Mice,  Outperforms Benchmark Therapy

CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy Annual Meeting

CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022

CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment

-Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported at ESMO Sarcoma and Rare Cancers